Glenmark Pharma receives tentative ANDA approval for Clobetasol Propionate Foam
Capital MarketGlenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux-E1 Foam, 0.05%, of Mylan Pharmaceuticals, Inc.
According to IQVIATM sales data for the 12 month period ending September 2018, the Olux-E Foam, 0.05% market2 achieved annual sales of approximately $13.2 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
